Action mechanism of the potent platelet aggregation inhibitor from Trimeresurus gramineus snake venom.
The platelet aggregation inhibitor (PAI) purified from T. gramineus snake venom inhibited platelet aggregation even when it was added after platelet shape change had occurred. It inhibited the initial platelet aggregation phase in rabbit platelet-rich plasma (PRP), but not the second lytic phase induced by thimerosal (0.5 mM), a -SH reagent. In human platelet-rich plasma, the venom inhibitor also inhibited the platelet aggregation induced by ADP, collagen, epinephrine or ristocetin. The epinephrine-induced platelet aggregation was more susceptible to the venom inhibitor. The venom inhibitor (10 micrograms/ml) as well as N-ethylmaleimide (1.2 mM), a -SH reagent, completely inhibited the thrombin-induced clot retraction of PRP. It is concluded that PAI acts on a common step of platelet aggregation. It acts on membrane -SH containing macromolecule which directly mediates the platelet aggregation subsequent to platelet shape change.
D000818:Animals; D000925:Anticoagulants; D001665:Binding Sites; D001792:Blood Platelets / Q000502:physiology; D003435:Crotalid Venoms / Q000494:pharmacology*; D006801:Humans; D046911:Macromolecular Substances; D010974:Platelet Aggregation / Q000187:drug effects*; D011817:Rabbits; D013438:Sulfhydryl Compounds
D000925:Anticoagulants; D003435:Crotalid Venoms; D046911:Macromolecular Substances; D013438:Sulfhydryl Compounds